Precision Antibody’s Post

View organization page for Precision Antibody, graphic
Precision Antibody

679 followers

It is remarkable that in less than a week, the Food and Drug Administration has granted approval to two novel B-call maturation antigen (BCMA) drugs for Multiple Myeloma. On August 9, the FDA granted accelerated approval to talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. Today Augsut 14th, the FDA granted approval to Pfizer's Elrexfio, or elranatamab for MM patients for have received at least four lines of therapy. Both drugs are bispecific antibodies, delivered under the skin and engaging T cells to target BCMA-expressing cancer cells. Consult the FDA Approval alerts link for details for Oncology (Cancer) / Hematologic Malignancies Approval Notifications | FDA for details on the drugs. These approvals should bring new hopes and therapeutic options to Multiple Myeloma patients. #fdaapproval #antibodies #multiplemyeloma

Paul Arnaboldi, Ph.D.

Assistant Professor of Microbiology and Immunology

1y

Does precision antibody still do contract work? Your webpage is not functional any longer, or at least hasn't worked for the last two days.

Like
Reply

To view or add a comment, sign in

More Relevant Posts

Precision Antibody

679 followers

View Profile

Explore topics